Advancing a broad portfolio with purpose and precision
With deep research expertise and a pioneering mindset, we advance a broad portfolio, generate rigorous translational and clinical data, and innovate in clinical development to accelerate proof‑of‑concept and global registration.
Our pipeline
Our programs
ANB033 is a novel anti‑CD122 antagonist that targets the shared beta subunit of the IL‑15 and IL‑2 receptors.
- These cytokines drive the proliferation and survival of key immune cell subsets, including CD8+ and CD4+ T cells, NK cells and ILC2s, that play central roles in autoimmune and inflammatory diseases
- By modulating this pathway, ANB033 has the potential to reduce inflammation and help maintain durable responses
Rosnilimab is a first‑in‑class antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues.
- By reducing these disease‑driving cells while sparing naïve T cells, investigational rosnilimab aims to restore immune homeostasis without broadly suppressing the immune system
- Through this targeted approach, rosnilimab reduces T‑cell activity, limits B‑cell recruitment/maturation and decreases plasma‑cell–mediated autoantibody production, addressing multiple drivers of autoimmune pathology
ANB101 is a BDCA2‑modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
- By engaging BDCA2, a molecule expressed primarily on pDCs, ANB101 aims to potently inhibit interferon secretion and downstream immune activation, addressing a central driver of autoimmune and inflammatory disease
Find out more about access to our investigational medicines